Arcus Biosciences, Inc.

ABOUT

Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer.

Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.

3928 Point Eden Way, Hayward, CA 94545 1800 Sierra Point Parkway, Brisbane, CA 94005 US
NEWS
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’s pipeline products.
Arcus Biosciences and Genentech, a Roche company, are partnering on two clinical trials for colorectal and pancreatic cancer. They will evaluate Arcus’s AB928 in various combinations.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
Companies strengthen their leadership teams and boards of directors with this week’s slate of Movers & Shakers.
Biopharma companies make changes to their C-suite leadership teams, with hires at uBiome, Enzyre, Sobi, Amylyx, Mission Therapeutics, and more.
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
Sage Therapeutics has been on a roll with good news lately.
AWARDS
  • NextGen Class of 2017
JOBS
IN THE PRESS